Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

AbbVie

Status: Withdrawn

Conditions: Psoriasis

Treatments: Biological: Comparator 1; Drug: Risankizumab; Drug: Comparator 2

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04799990

P16-772

Details and patient eligibility

About

Study is not recruiting and using secondary data sources only

Full description

Study is not recruiting and using secondary data sources only

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Study is not recruiting and using secondary data sources only

Trial design

0 participants in 3 patient groups

Risankizumab

Description:

Participants will receive risankizumab as prescribed by their physician.

Treatment:

Drug: Risankizumab

Comparator Group 1

Description:

Participants will receive biologics other than interleukin (IL)-23 antagonists as prescribed by their physician.

Treatment:

Biological: Comparator 1

Comparator Group 2

Description:

Participants will receive non-biologic systemic small molecules as prescribed by their physician.

Treatment:

Drug: Comparator 2